Literature DB >> 17996587

Pathophysiology of multiple myeloma bone disease.

Suzanne Lentzsch1, Lori A Ehrlich, G David Roodman.   

Abstract

Multiple myeloma is a plasma cell malignancy characterized by the frequent development of osteolytic bone lesions. The multiple myeloma-induced bone destruction is a result of the increased activity of osteoclasts that occurs adjacent to multiple myeloma cells. This activity is accompanied by suppressed osteoblast differentiation and activity, resulting in severely impaired bone formation and development of devastating osteolytic lesions. Recently the biologic mechanism involved in the imbalance between osteoclast activation and osteoblast inhibition induced by multiple myeloma cells has begun to be clarified. In this article, the pathophysiology underlying the imbalanced bone remodeling and potential new strategies for the treatment of bone disease in multiple myeloma are reviewed.

Entities:  

Mesh:

Year:  2007        PMID: 17996587     DOI: 10.1016/j.hoc.2007.08.009

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  12 in total

Review 1.  Bone disease from monoclonal gammopathy of undetermined significance to multiple myeloma: pathogenesis, interventions, and future opportunities.

Authors:  Alex R Minter; Haley Simpson; Brendan M Weiss; Ola Landgren
Journal:  Semin Hematol       Date:  2011-01       Impact factor: 3.851

Review 2.  Dissecting the multiple myeloma-bone microenvironment reveals new therapeutic opportunities.

Authors:  G Shay; L Hazlehurst; C C Lynch
Journal:  J Mol Med (Berl)       Date:  2015-10-01       Impact factor: 4.599

3.  Dominant role of CD47-thrombospondin-1 interactions in myeloma-induced fusion of human dendritic cells: implications for bone disease.

Authors:  Anjli Kukreja; Soroosh Radfar; Ben-Hua Sun; Karl Insogna; Madhav V Dhodapkar
Journal:  Blood       Date:  2009-08-06       Impact factor: 22.113

Review 4.  Effects on bone metabolism of new therapeutic strategies with standard chemotherapy and biologic drugs.

Authors:  Stefania Ciolli
Journal:  Clin Cases Miner Bone Metab       Date:  2013-09

5.  Fenretinide inhibits myeloma cell growth, osteoclastogenesis and osteoclast viability.

Authors:  Xin Li; Wen Ling; Angela Pennisi; Sharmin Khan; Shmuel Yaccoby
Journal:  Cancer Lett       Date:  2009-05-15       Impact factor: 8.679

6.  Bone building with bortezomib.

Authors:  G David Roodman
Journal:  J Clin Invest       Date:  2008-02       Impact factor: 14.808

7.  Multiple myeloma-derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease.

Authors:  Jing Fu; Shirong Li; Rentian Feng; Huihui Ma; Farideh Sabeh; G David Roodman; Ji Wang; Samuel Robinson; X Edward Guo; Thomas Lund; Daniel Normolle; Markus Y Mapara; Stephen J Weiss; Suzanne Lentzsch
Journal:  J Clin Invest       Date:  2016-04-04       Impact factor: 14.808

8.  Bortezomib in the management of multiple myeloma.

Authors:  Jacob P Laubach; Constantine S Mitsiades; Teru Hideshima; Robert Schlossman; Dharminder Chauhan; Nikhil Munshi; Irene Ghobrial; Nicole Carreau; Kenneth C Anderson; Paul G Richardson
Journal:  Cancer Manag Res       Date:  2009-09-08       Impact factor: 3.989

9.  Relationship between abnormal osteoblasts and cellular immunity in multiple myeloma.

Authors:  Rong Fu; Shan Gao; Fengping Peng; Jing Li; Hui Liu; Huaquan Wang; Linmin Xing; Zonghong Shao
Journal:  Cancer Cell Int       Date:  2014-08-14       Impact factor: 5.722

10.  Patients With Multiple Myeloma Have More Complications After Surgical Treatment of Hip Fracture.

Authors:  Kwan Jun Park; Mariano E Menendez; Simon C Mears; C Lowry Barnes
Journal:  Geriatr Orthop Surg Rehabil       Date:  2016-07-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.